A Study of the Efficacy and Safety of Different Dosages of Rivaroxaban in Patients with Atrial Fibrillation
Objective To investigate the effect and safety of different dosages of rivaroxaban on embolization prevention in patients with atrial fibrillation.Methods Atrial fibrillation patients with oral rivaroxaban in Wuhan Asia Heart Hospital and Wuhan Asia Heart General Hospital from March,2018 to December,2021 were enrolled and divided into 10mg-dose group and 15mg-dose group according to the daily prescription dosage information.The incidence of thrombosis,bleeding and all-cause death in these two groups during follow-up duration was recorded and compared,and the related influencing factors were analyzed.Results The incidence of thrombus,hemorrhage and all-cause death in 2 groups was higher in 10mg-dose group than in 15mg-dose group,with no statistical significance(x2=0.418,3.757,2.084,all P＞0.05).The incidence of total adverse events was higher in 10mg-dose group than in 15mg low-dose group,and the difference was statistically significant(x2=5.071,P=0.024).Multivariate logistic regression showed that D-dimer level[OR(95％CI)=1.07(1.00-1.14)]was an independent risk factor for thrombotic events in patients with atrial fibrillation(P=0.035).Diabetes mellitus[OR(95％CI)=3.44(1.24-9.51)]was an independent risk factor for all-cause mortality in patients with atrial fibrillation(P=0.017).Conclusion In clinical practice,10mg rivaroxaban dosage has no significant benefit,and the efficacy and safety of patients are not better or worse than 15mg dosage.Advanced age,elevated D-dimer level,and history of diabetes are risk factors for adverse events.
NETL
NSTL
万方数据
维普
